Condition (MeSH)
Ossification, Heterotopic
ClinicalTrials.gov lists 49 trials for Ossification, Heterotopic or a narrower condition beneath it. Clementia Pharmaceuticals Inc. has the most among industry and government lead sponsors, with 5.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
38 of the 49 trials are tagged with Ossification, Heterotopic itself; the rest are tagged with a narrower condition beneath it.
When did Ossification, Heterotopic trials start? (19)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 2 |
| 2024 | 1 |
| 2023 | 4 |
| 2022 | 6 |
| 2021 | 4 |
| 2020 | 2 |
| 2019 | 3 |
| 2018 | 2 |
| 2017 | 4 |
| 2016 | 2 |
Showing 10 of 19 earlier years.
No forecast is made for this condition: it averages 2.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Ossification, Heterotopic trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 5 |
| Phase 2/3 | 1 |
| Phase 3 | 4 |
| Phase 4 | 4 |
| Not applicable | 17 |
| Observational | 16 |
How many Ossification, Heterotopic trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 6 |
| Active, not recruiting | 4 |
| Completed | 23 |
| Terminated | 3 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Ossification, Heterotopic trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Clementia Pharmaceuticals Inc. | 5 |
| Regeneron Pharmaceuticals | 4 |
| Ashibio Inc | 2 |
| Aesculap AG | 1 |
| Assaf-Harofeh Medical Center | 1 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Ossification, Heterotopic? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Palovarotene | 3 |
| Garetosmab | 3 |
| Andecaliximab | 2 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| 1: Naproxen | 2 |
| "celecoxib", "Celebrex®" | 2 |
| Radiation | 2 |
| Ibuprofen 2% | 1 |
| Intra-articular Tranexamic acid application | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Ossification, Heterotopic trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Epiphyses Premature Fusion | 21 | 1 |
| Corona virus infection | 18 | 2 |
| Pneumonia | 8 | 2 |
| Condition aggravated | 7 | 2 |
| Exposure to communicable disease | 7 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Ossification, Heterotopic? (148)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Heterotopic ossifications in anterior and lateral approach total ankle replacement: A retrospective evaluation. | The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons | 2026 | Yes |
| The influence of nerve surgical techniques at time of amputation on the prevalence of heterotopic ossification in transtibial amputees. | Injury | 2025 | Yes |
| The significance of heterotopic ossification following total ankle arthroplasty: a systematic review and meta-analysis. | European journal of orthopaedic surgery & traumatology : orthopedie traumatologie | 2024 | Yes |
| The Fibrodysplasia Ossificans Progressiva Physical Function Questionnaire (FOP-PFQ): A patient-reported, disease-specific measure. | Bone | 2023 | Yes |
| Study methodology and insights from the palovarotene clinical development program in fibrodysplasia ossificans progressiva. | BMC medical research methodology | 2023 | Yes |
Showing 5 of 148 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.